Skip to main content
. 2015 Aug 13;17(1):108. doi: 10.1186/s13058-015-0623-y

Table 1.

Characteristics of 271 patients with ductal carcinoma in situ (DCIS), with and without invasive breast cancer

DCIS
All patients DCIS only DCIS with invasive cancer
N (%) N (%) N (%)
Total 271 (100.0) 120 (100.0) 151 (100.0)
Age at diagnosis, years
 <40 24 (8.9) 4 (3.3) 20 (13.2)
 40–49 90 (33.2) 43 (35.8) 47 (31.1)
 50–64 90 (33.2) 36 (30.0) 54 (35.8)
 ≥65 67 (24.7) 37 (30.8) 30 (19.9)
Year of breast cancer diagnosis
 2000–2003 226 (83.4) 97 (80.8) 129 (85.4)
 2004–2007 43 (15.9) 22 (18.3) 21 (13.9)
 2008–2011 2 (0.7) 1 (0.8) 1 (0.7)
Race
 Missing 5 (1.8) 2 (1.7) 3 (2.0)
 Hispanic 10 (3.7) 4 (3.3) 6 (4.0)
 Non-Hispanic (NH) white 199 (73.4) 81 (67.5) 118 (78.1)
 NH black 4 (1.5) 3 (2.5) 1 (0.7)
 NH Asian/Pacific Islander 53 (19.6) 30 (25.0) 23 (15.2)
Socioeconomic status
 Missing 30 (11.1) 19 (15.8) 11 (7.3)
 1 (Lowest) 4 (1.5) 2 (1.7) 2 (1.3)
 2 15 (5.5) 8 (6.7) 7 (4.6)
 3 23 (8.5) 9 (7.5) 14 (9.3)
 4 40 (14.8) 10 (8.3) 30 (19.9)
 5 (Highest) 159 (58.7) 72 (60.0) 87 (57.6)
Hormone receptors
 Missing 12 (4.4) 0 0 12 (7.9)
 Either ER or PR positive 137 (50.6) 65 (54.2) 72 (47.7)
 Both ER and PR negative 122 (45.0) 55 (45.8) 67 (44.4)
Stage
 Missing 4 (1.5) 0 0 4 (2.6)
 Stage 0 120 (44.3) 120 (100.0) 0 0
 Stage I 69 (25.5) 0 0 69 (45.7)
 Stage II 69 (25.5) 0 0 69 (45.7)
 Stage III 8 (3.0) 0 0 8 (5.3)
 Stage IV 1 (0.4) 0 0 1 (0.7)
Grade
 Missing 2 (0.7) 1 (0.8) 1 (0.7)
 1 56 (20.7) 27 (22.5) 29 (19.2)
 2 130 (48.0) 57 (47.5) 73 (48.3)
 3 83 (30.6) 35 (29.2) 48 (31.8)
HER2 gain
 No gain 182 (67.2) 83 (69.2) 99 (65.6)
 Gain 89 (32.8) 37 (30.8) 52 (34.4)

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2